The latest iteration of comprehensive chromosomal screening (CCS) is called “next generation sequencing” (NGS). A recent study set out to clinically validate the technology; in a blinded, non-selection study, embryos were transferred without knowledge of NGS results to determine the predictive value (proportion of results that are true positive and true negative).
A recent study compared the efficacy of two types of preimplantation genetic screening (PGS) used with IVF and single embryo transfer: next generation sequencing (NGS), and array Comparative Genomic Hybridization (aCGH). The researchers determined that clinical and ongoing pregnancy rates are comparable.
A recent study looked at embryo selection in an IVF cycle based on two different criteria: embryo morphology and chromosomal makeup. Researchers looked at day 5 embryos (blastocysts) that were graded using standard morphology, then tested with comprehensive chromosomal screening (CCS). The study concluded that when embryos are selected to transfer based solely on morphology, in 41% of cases the embryos chosen will be aneuploid (abnormal).
Dr. Bruce Albrecht from Albrecht Women's Care talks about PGS. He talks about the advantages that PGS has including, a decreased amount of time that it takes to get pregnant as well as reducing the rate of miscarriages due to since the genetically abnormal embryos are not implanted.
Dr. John Norian of HRC Fertility discusses the recent advances that have taken place with PGS, genetic testing. The ability to examine an embryo further and to identify any abnormalities is an enormous advance in fertility treatment.